Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.65 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.65 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7280806 | 0.79 | PDE5A (1.00) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| Hydrochloric Acid SCHEMBL7279655 | 0.78 | PDE5A (0.97) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL785671 | 0.76 | KDM4E (0.55) | — | |
| SCHEMBL7277566 | 0.75 | PDE5A (1.00) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL17799858 | 0.74 | PDE5A (0.72) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| Hydrochloric Acid SCHEMBL7278029 | 0.74 | PDE5A (1.00) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL31471948 | 0.73 | APP (0.56) | PDE5A | |
| SCHEMBL786130 | 0.73 | APP (0.56) | PDE5A | |
| SCHEMBL801842 | 0.73 | PIK3CD (0.52) | — | |
| SCHEMBL7280050 | 0.73 | PDE5A (0.84) | PDE5ATBXAS1PDE3BPDE3APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-8524720-B2 | Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524720-B2 | Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524720-B2 | Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-7951820-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-31 | — | — | US | disclosed |
| US-6660731-B2 | Alzheimer's disease; anticancer agents; antidiabetic agents | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-09 | — | — | US | disclosed |
| US-6638926-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-10-28 | — | — | US | disclosed |
| US-6613776-B2 | Protein serine/threonine kinase inhibitors used for treating diseases such as cancer, diabetes and Alzheimer's disease | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-02 | — | — | US | disclosed |
| US-6610677-B2 | Enhancing glycogen synthesis, lowering blood levels of glucose, treating colon, ovarian, or breast cancer, treating diabetes, treating schizophrenia | VERTEX PHARMACEUTICALS INCORPORATED | 2003-08-26 | — | — | US | disclosed |
| US-20030083327-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-01 | — | — | US | disclosed |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-24 | — | — | US | disclosed |
| US-20030073687-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-17 | — | — | US | disclosed |
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-03 | — | — | US | disclosed |
| US-20030064982-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-03 | — | — | US | disclosed |
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3A | PDE5A 3861/4885TBXAS1 3149/4885PDE3B 3980/4885 |
| US-20030064982-A1 | Pyrazole compounds useful as protein kinase inhibitors | MAP3K20, CDK2, MAP2K2 | PDE5A 2818/4885TBXAS1 1216/4885PDE3B 2235/4885 |
| US-20030083327-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | PDE5A 3307/4885TBXAS1 3884/4885PDE3B 3105/4885 |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | PDE5A 3100/4885TBXAS1 1520/4885PDE3B 2721/4885 |
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | PDE5A 4073/4885TBXAS1 2687/4885PDE3B 4139/4885 |
| US-20030073687-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | PDE5A 4228/4885TBXAS1 1117/4885PDE3B 3826/4885 |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | GSK3B, GSK3A, GSKIP | PDE5A 2118/4885TBXAS1 1284/4885PDE3B 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.